503A vs 503B Pharmacy: Does It Change Your Compounded Semaglutide?

It changes three things that matter to you: how your prescription has to be justified, how the preparation is made and overseen, and how likely your supply is to change again. What it does not change is the most important thing to keep in mind either way, which is that compounded medications are not FDA-approved and have not been reviewed for safety, effectiveness, and quality before reaching you.

The short version of the distinction: a 503A pharmacy compounds for an identified individual patient against a prescription. A 503B outsourcing facility compounds at larger scale and registers with the FDA to do so.

What each one is

503A refers to traditional pharmacy compounding. A licensed pharmacy prepares a medication for a specific named patient based on a prescriber’s prescription. Oversight is primarily through state boards of pharmacy. The preparation is made for you rather than made in bulk and assigned to you.

503B refers to outsourcing facilities. These register with the FDA, are subject to federal inspection, and compound at larger scale, which is why they could supply the volume that telehealth platforms needed during the shortages.

Neither category produces an FDA-approved drug. The approval process applies to products like Wegovy, Ozempic, Zepbound, and Mounjaro, not to compounded preparations from either type of facility.

Why yours may have moved

Large-scale compounding of these medications grew because semaglutide and tirzepatide were on the FDA drug shortage list, which created a legal basis for it. Those shortages were declared resolved, and the FDA set out wind-down timelines for compounders.

Since then the agency has proposed excluding these substances from the list that governs what outsourcing facilities may compound from bulk drug substances, on the basis that approved products exist. The direction of travel has been away from large-scale supply and toward narrower, patient-specific compounding where a documented clinical need cannot be met by an approved product.

A move from a 503B to a 503A pharmacy generally reflects that shift rather than anything about you or your treatment.

The three things it changes for you

Your prescription needs a patient-specific justification. Under 503A, the preparation is made for you against your prescription. Expect your provider to document why a compounded preparation rather than an approved product is appropriate for your situation. Affordability, on its own, is not the kind of clinical need this framework contemplates.

The preparation may differ. Different pharmacy, potentially different concentration, fill volume, labeling, and storage instructions. This is the safety-relevant part and is covered below.

Supply may be less predictable. Patient-specific compounding does not scale the way outsourcing facility supply did. Lead times and availability can be less consistent.

The concentration question, again

If your medication comes in a vial and you draw your dose with a syringe, your dose is a volume, and what that volume contains depends on the concentration of the preparation.

Change the pharmacy and you may change the concentration. Draw your usual amount on habit and you have changed your dose without meaning to. The FDA has alerted patients and prescribers to dosing errors with compounded semaglutide, some resulting in hospitalization, and a published case series describes the same category of error reported to a poison control center.

Consider this scenario: a patient receives their first shipment from the new pharmacy. The vial is a similar size and the liquid looks the same. They draw to the mark they have used for four months. Nothing in that sequence involved carelessness, and it still produced a dosing error, because the only thing that would have caught it was a deliberate check that nobody prompted.

Whenever a supplier changes, confirm in writing with the pharmacy what volume equals your prescribed dose for that specific preparation, before the first dose.

What to ask when the pharmacy changes

1. What is the concentration, and does the volume I draw change?
2. What are the storage instructions, and are they different from before?
3. What is the beyond-use date, and how does it compare to my supply period?
4. What is the lead time for refills now?
5. Who do I call with a question about the preparation itself?

Question two catches a real difference: storage requirements vary between compounders and are sometimes stricter than what you were following. Our guide to storing compounded semaglutide or tirzepatide at home covers the general setup, and the preparing pharmacy’s own instruction governs where they differ.

Is one type safer?

Not a question with a clean answer, and be skeptical of anyone who gives you one.

Outsourcing facilities operate under federal manufacturing standards and FDA inspection. Traditional pharmacies operate under state oversight and prepare smaller quantities for named patients. Both models have produced good practice and both have produced problems.

What is more useful than the category is the specific pharmacy: its accreditation, its testing practices, and whether your provider can tell you about it without hedging. Our guide on verifying that a compounding pharmacy is safe and legitimate covers what to ask.

When to call

Call rather than wait if a new shipment differs from your last one and a dose is due, if the label uses different units or a different concentration, if the storage instructions changed and your medication has already been sitting where the old instructions allowed, or if you have already injected from a new preparation and are not sure the amount was right.

The short version

503A means made for you against a prescription, with state oversight. 503B means an FDA-registered facility compounding at scale. Neither is FDA-approved medication. The practical consequences for you are a prescription that needs patient-specific justification, a preparation that may have changed, and a supply chain that may be less predictable. Treat any change of preparation as a dosing question before you treat it as anything else.

If you want the pharmacy relationship handled with the prescription rather than left for you to reconcile, TrimRx coordinates prescription, pharmacy, and delivery together.

This information is for educational purposes and is not medical advice. Consult with a healthcare provider before starting any medication. Individual results may vary.